Opinion|Videos|November 8, 2024
CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024
Panelists discuss how the KARMMA-3 study’s design, patient population, and efficacy outcomes—including overall survival data—inform the approval of ide-cel, as well as the implications of CARTITUDE-4’s recent findings on treatment selection and approaches for cilta-cel in chimeric antigen receptor T-cell therapy.
Advertisement
Episodes in this series
- Dr Ajai Chari to Dr Martin: Let’s dive deeper into the KARMMA-3 study that got ide-cel approved. Dr Martin: Can you please review the KARMMA-3 study design, patient population, and efficacy outcomes including overall survival (OS) data?
Resource Link:
Ailawadhi S et al. KarMMa-3 Updated Analysis 2024 - online ahead of print Rodriguez-Otero P et al. KARMMA-3 NEJM 2023 Idel-cel rrMM. Rodiguez-Otero P et al. KarMMa-3 Updated Analysis. ASH 2023 Oral Abstract.
- Dr Ajai Chari to Dr Callander: Now that we have discussed KARMMA-3, let’s review CARTITUDE-4. Dr Callander: Can you please review the CARTITUDE-4 study design, patient population, and recently presented IMS 2024 CARTITUDE-4 OS data updates
Resource Link
OA-65 IMS 2024 CARTITUDE 4 or (see page 14)
Advertisement
Related to this article
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Plinabulin plus docetaxel received fast track designation for pretreated nonsquamous NSCLC without actionable genomic alterations.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
2
CNS Control and Daily Tolerability Guide Treatment Sequencing in HER2-Mutated NSCLC
3
Tabelecleucel BLA Is Resubmitted to FDA for EBV+ Post-Transplant Lymphoproliferative Disease
4
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
5